Streetbeat News

Analyst Ratings

NXPI

Cantor Fitzgerald analyst C J Muse reiterated an Overweight rating on NXP Semiconductors (NXPI) and maintained a $270 price target.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 7:06 pm

NVDA

Cantor Fitzgerald analyst C J Muse has reiterated an Overweight rating on NVIDIA (NASDAQ:NVDA) and maintained a $900 price target.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 7:05 pm

LRCX

Cantor Fitzgerald analyst C J Muse has reiterated a Neutral rating on Lam Research (NASDAQ:LRCX) and maintained a $900 price target.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 7:03 pm

OKTA

Recent analysis of Okta's (NASDAQ:OKTA) options activity shows a bearish trend among financial giants, with 62% of trades indicating bearish sentiment. The analysis highlighted unusual trading volume with a focus on a price window from $75.0 to $165.0. The largest trades were predominantly calls, with varying sentiments. Okta, a cloud-native security company, has seen its stock price increase by 1.02% to $109.6. Market experts have issued mixed ratings, with a consensus target price of $113.6. The next earnings report is expected in 86 days.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 7:02 pm

EVBG

Everbridge (NASDAQ:EVBG) has been the subject of diverse analyst opinions over the past quarter, with recent evaluations showing a unanimous indifferent stance. The average 12-month price target for EVBG has risen 37.5% to $31.9, with analysts from Canaccord Genuity and Truist Securities raising their targets. Despite a negative revenue trend and a high debt-to-equity ratio, Everbridge's net margin and ROE outperform industry standards. The company specializes in enterprise software for critical event management, primarily serving the U.S. market.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 7:02 pm

AHCO

AdaptHealth (NASDAQ:AHCO) received mixed analyst ratings over the past three months, with a shift towards a more bullish outlook in the last 30 days. The average 12-month price target for AHCO has been raised to $12.00, up 20% from the previous $10.00, with high estimates reaching $13.00. Analysts from RBC Capital, UBS, and Truist Securities have adjusted their ratings and price targets, reflecting changing market conditions and company performance. AdaptHealth, a provider of home healthcare solutions, has shown positive revenue growth and a strong net margin but faces challenges with its ROE, ROA, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 7:01 pm

APPN

Over the last three months, 4 analysts have provided diverse opinions on Appian (NASDAQ:APPN), with recent ratings ranging from bullish to bearish. The average 12-month price target is now $45.5, down 4.21% from the previous $47.50. Analyst actions include both upgrades and downgrades, reflecting dynamic market conditions and Appian's performance. Despite positive revenue growth of 15.53% as of December 31, 2023, Appian faces challenges in profitability, debt management, and operational efficiency compared to industry benchmarks.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 7:01 pm

DLTR

Four analysts have recently updated their ratings on Dollar Tree (NASDAQ:DLTR), showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target has been raised to $161.5, indicating a 16.19% increase from the previous target of $139.00. Analysts from Wells Fargo, Gordon Haskett, JP Morgan, and Truist Securities have adjusted their price targets and ratings, reflecting optimism about Dollar Tree's future performance. The company has demonstrated strong financial health with a revenue growth rate of 5.4% and a net margin of 2.9%, although it faces challenges with below-average ROE and ROA.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 7:01 pm

PTVE

Pactiv Evergreen (NASDAQ:PTVE) has been analyzed by 9 analysts, showing a diverse range of perspectives with an average 12-month price target of $15.94, indicating a 26.71% increase from the previous target. The company operates in foodservice and beverage cartons, facing revenue challenges but showing strong profitability and effective cost management. Analysts' ratings and price targets have been adjusted based on recent developments and financial performance.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 7:00 pm

KLAC

Cantor Fitzgerald analyst C J Muse has reiterated a Neutral rating on KLA Corporation (NASDAQ:KLAC) and maintained a price target of $625.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 7:00 pm